- Home
- ARTV vs OBIO Comparison
ARTV vs OBIO Comparison
Compare ARTV & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- OBIO
- Stock Information
- Founded
- ARTV 2019
- OBIO 2017
- Country
- ARTV United States
- OBIO United States
- Employees
- ARTV N/A
- OBIO N/A
- Industry
- ARTV
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- ARTV
- OBIO Health Care
- Exchange
- ARTV NYSE
- OBIO Nasdaq
- Market Cap
- ARTV 186.1M
- OBIO 198.2M
- IPO Year
- ARTV 2024
- OBIO N/A
- Fundamental
- Price
- ARTV $3.77
- OBIO $4.72
- Analyst Decision
- ARTV Strong Buy
- OBIO Strong Buy
- Analyst Count
- ARTV 6
- OBIO 4
- Target Price
- ARTV $21.00
- OBIO $16.25
- AVG Volume (30 Days)
- ARTV 83.1K
- OBIO 50.3K
- Earning Date
- ARTV 03-04-2025
- OBIO 03-26-2025
- Dividend Yield
- ARTV N/A
- OBIO N/A
- EPS Growth
- ARTV N/A
- OBIO N/A
- EPS
- ARTV N/A
- OBIO N/A
- Revenue
- ARTV $2,601,000.00
- OBIO $2,647,000.00
- Revenue This Year
- ARTV N/A
- OBIO $22.61
- Revenue Next Year
- ARTV N/A
- OBIO $16.64
- P/E Ratio
- ARTV N/A
- OBIO N/A
- Revenue Growth
- ARTV N/A
- OBIO N/A
- 52 Week Low
- ARTV $3.37
- OBIO $3.96
- 52 Week High
- ARTV $17.31
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- OBIO 38.59
- Support Level
- ARTV N/A
- OBIO $5.20
- Resistance Level
- ARTV N/A
- OBIO $5.98
- Average True Range (ATR)
- ARTV 0.00
- OBIO 0.42
- MACD
- ARTV 0.00
- OBIO -0.07
- Stochastic Oscillator
- ARTV 0.00
- OBIO 2.70
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.